利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

1686 条记录 (耗时 0.048 秒)

    Genetic probe used in the detection of adrenal hyperplasia
    1.
    发明授权
    Genetic probe used in the detection of adrenal hyperplasia 失效
    用于检测肾上腺增生的遗传探针

    公开(公告)号：US4720454A

    公开(公告)日：1988-01-19

    申请号：US601650

    申请日：1984-04-18

    申请人： Perrin C. White ,  Bo Dupont ,  Maria I. New

    发明人： Perrin C. White ,  Bo Dupont ,  Maria I. New

    IPC分类号： C12N9/02 ,  C12Q1/68 ,  C12N15/00

    CPC分类号： C12N9/0087 ,  C12Q1/6883 ,  C12Q2600/156 ,  C12Q2600/172

    摘要： A cDNA clone is isolated encoding a bovine adrenal cytochrome P-450 specific for steroid 21-hydroxylation (P-450.sub.C21). This plasmid pC21a contains an insert of 520 base pairs. It hybridizes with mRNA encoding P-450.sub.C21. The peptide encoded by the insert is highly homologous to two peptides isolated from porcine P-450.sub.C21 and shows limited homology to the P-450 induced by phenobarbital in rat liver. This probe and its human equivalents can be used to screen in utero i.e. pre-natal as well as post-natal patients for adrenal hyperplasia since it reacts well with human DNA as shown. These probes can also be useful for an industrial fermentation process to produce cortisone in quantity.

    摘要翻译： 分离cDNA克隆，其编码对类固醇21-羟基化（P-450C21）特异性的牛肾上腺细胞色素P-450。 该质粒pC21a含有520个碱基对的插入片段。 它与编码P-450C21的mRNA杂交。 由插入片段编码的肽与从猪P-450C21分离的两种肽高度同源，并且与大鼠肝脏中苯巴比妥诱导的P-450显示有限的同源性。 该探针及其人类等同物可用于筛选子宫内，即出生前以及出生后患者的肾上腺增生，因为如图所示，它与人类DNA发生反应良好。 这些探针也可用于工业发酵过程以量产生可的松。

    METHODS FOR REDUCING OXIDATIVE DAMAGE
    4.
    发明申请
    METHODS FOR REDUCING OXIDATIVE DAMAGE 有权

    公开(公告)号：US20210015887A1

    公开(公告)日：2021-01-21

    申请号：US16798085

    申请日：2020-02-21

    申请人： Cornell Research Foundation, Inc.

    发明人： Hazel H. Szeto

    IPC分类号： A61K38/07 ,  A61K38/08 ,  A61K38/10 ,  C07K5/11

    摘要： The invention provides a method for reducing oxidative damage in a mammal, a removed organ, or a cell in need thereof The method comprises administering an effective amount of an aromatic cationic peptide. The aromatic cationic peptide has (a) at least one net positive charge; (b) a minimum of three amino acids; (c) a maximum of about twenty amino acids, (d) a relationship between the minimum number of net positive charges (pm) and the total number of amino acid residues (r) wherein 3 pm is the largest number that is less than or equal to r+1; (e) a relationship between the minimum number of aromatic groups (a) and the total number of net positive charges (pt) wherein 3a or 2a is the largest number that is less than or equal to pt+1, except that when a is 1, pt may also be 1; and (f) at least one tyrosine or tryptophan amino acid.

    METHODS FOR REDUCING OXIDATIVE DAMAGE
    6.
    发明申请
    METHODS FOR REDUCING OXIDATIVE DAMAGE 审中-公开

    公开(公告)号：US20190328821A1

    公开(公告)日：2019-10-31

    申请号：US15956941

    申请日：2018-04-19

    申请人： Cornell Research Foundation, Inc.

    发明人： Hazel H. Szeto

    IPC分类号： A61K38/07 ,  C07K5/11 ,  A61K38/08 ,  A61K38/10

    摘要： The invention provides a method for reducing oxidative damage in a mammal, a removed organ, or a cell in need thereof. The method comprises administering an effective amount of an aromatic cationic peptide. The aromatic cationic peptide has (a) at least one net positive charge; (b) a minimum of three amino acids; (c) a maximum of about twenty amino acids, (d) a relationship between the minimum number of net positive charges (pm) and the total number of amino acid residues (r) wherein 3 pm is the largest number that is less than or equal to r+1; (e) a relationship between the minimum number of aromatic groups (a) and the total number of net positive charges (pt) wherein 3a or 2a is the largest number that is less than or equal to pt+1, except that when a is 1, pt may also be 1; and (f) at least one tyrosine or tryptophan amino acid.